Literature DB >> 15333838

Plasminogen is a critical host pathogenicity factor for group A streptococcal infection.

Hongmin Sun1, Ulrika Ringdahl, Jonathon W Homeister, William P Fay, N Cary Engleberg, Angela Y Yang, Laura S Rozek, Xixi Wang, Ulf Sjöbring, David Ginsburg.   

Abstract

Group A streptococci, a common human pathogen, secrete streptokinase, which activates the host's blood clot-dissolving protein, plasminogen. Streptokinase is highly specific for human plasminogen, exhibiting little or no activity against other mammalian species, including mouse. Here, a transgene expressing human plasminogen markedly increased mortality in mice infected with streptococci, and this susceptibility was dependent on bacterial streptokinase expression. Thus, streptokinase is a key pathogenicity factor and the primary determinant of host species specificity for group A streptococcal infection. In addition, local fibrin clot formation may be implicated in host defense against microbial pathogens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333838     DOI: 10.1126/science.1101245

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  170 in total

1.  NMR backbone dynamics of VEK-30 bound to the human plasminogen kringle 2 domain.

Authors:  Min Wang; Mary Prorok; Francis J Castellino
Journal:  Biophys J       Date:  2010-07-07       Impact factor: 4.033

2.  Tumor necrosis factor alpha modulates the dynamics of the plasminogen-mediated early interaction between Bifidobacterium animalis subsp. lactis and human enterocytes.

Authors:  Manuela Centanni; Simone Bergmann; Silvia Turroni; Sven Hammerschmidt; Gursharan Singh Chhatwal; Patrizia Brigidi; Marco Candela
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

3.  mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets.

Authors:  Andrew S Weyrich; Melvin M Denis; Hansjorg Schwertz; Neal D Tolley; Jason Foulks; Eliott Spencer; Larry W Kraiss; Kurt H Albertine; Thomas M McIntyre; Guy A Zimmerman
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

4.  Structural diversity of streptokinase and activation of human plasminogen.

Authors:  Sergio Lizano; Kenneth H Johnston
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

6.  Enolase as a plasminogen binding protein in Leishmania mexicana.

Authors:  Gilmer Vanegas; Wilfredo Quiñones; Cesar Carrasco-López; Juan Luis Concepción; Fernando Albericio; Luisana Avilán
Journal:  Parasitol Res       Date:  2007-07-27       Impact factor: 2.289

7.  Development of tag-free photoprobes for studies aimed at identifying the target of novel Group A Streptococcus antivirulence agents.

Authors:  Bryan D Yestrepsky; Colin A Kretz; Yuanxi Xu; Autumn Holmes; Hongmin Sun; David Ginsburg; Scott D Larsen
Journal:  Bioorg Med Chem Lett       Date:  2014-02-07       Impact factor: 2.823

8.  Activation of band 3 mediates group A Streptococcus streptolysin S-based beta-haemolysis.

Authors:  Dustin L Higashi; Nicolas Biais; Deborah L Donahue; Jeffrey A Mayfield; Charles R Tessier; Kevin Rodriguez; Brandon L Ashfeld; Jeffrey Luchetti; Victoria A Ploplis; Francis J Castellino; Shaun W Lee
Journal:  Nat Microbiol       Date:  2016-01-18       Impact factor: 17.745

9.  Contributions of different modules of the plasminogen-binding Streptococcus pyogenes M-protein that mediate its functional dimerization.

Authors:  Cunjia Qiu; Yue Yuan; Jaroslav Zajicek; Zhong Liang; Rashna D Balsara; Teresa Brito-Robionson; Shaun W Lee; Victoria A Ploplis; Francis J Castellino
Journal:  J Struct Biol       Date:  2018-07-30       Impact factor: 2.867

Review 10.  Thrombosis as an intravascular effector of innate immunity.

Authors:  Bernd Engelmann; Steffen Massberg
Journal:  Nat Rev Immunol       Date:  2012-12-07       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.